Squibb

Bristol Myers Squibb (BMS) is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. The company maintains a dominant presence in oncology, hematology, immunology, and cardiovascular disease, supported by a robust portfolio of blockbuster therapies such as Opdivo and Eliquis. Following the transformative acquisition of Celgene in 2019, BMS has significantly expanded its pipeline in cell therapy and protein degradation. The company continues to grow through strategic acquisitions, including MyoKardia, Karuna Therapeutics, and RayzeBio, targeting high-growth areas like neuroscience and radiopharmaceuticals. BMS is committed to advancing a diverse range of modalities to address significant unmet medical needs worldwide.